Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care (EleVATE GC)

November 28, 2023 updated by: Washington University School of Medicine
This study will provide high-quality, representative data on the capacity of Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care (EleVATE GC) to reduce perinatal depression, preterm birth, and low birthweight in African-American women. If findings from this study indicate that EleVATE GC is feasible and effective, this model could be implemented nationwide to help achieve mental and obstetric health parity for low-income women of color in the United States.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

390

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • Kansas City, Missouri, United States, 64108
        • University of Missouri-Kansas City/Truman Health Centers-Kansas City
      • Saint Louis, Missouri, United States, 63104
        • Affinia Healthcare
      • Saint Louis, Missouri, United States, 63111
        • Family Care Health Centers
      • Saint Louis, Missouri, United States, 63112
        • CareSTL Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • English or Spanish speaking
  • ≤18 weeks' gestation
  • Established prenatal care at EleVATE site
  • High-risk for postpartum depression by ≥1 risk factor (personal/family history, baseline EPDS≥10, low-income, 13-19 years old, single, history of physical/sexual abuse, unplanned/undesired pregnancy, history of pregnancy loss)
  • Ability to attend group prenatal visits at specified days/times
  • Willingness to be randomized
  • Ability to give informed consent
  • Any patient that has received prenatal care in a group setting previously

Exclusion Criteria:

  • Multiple gestation
  • Major fetal anomaly
  • Serious medical co-morbidity/psychiatric illness necessitating more care than can be safely provided in group setting
  • Serious medical co-morbidity necessitating more care than can be safely provided in group setting

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group Prenatal Care
Group prenatal care model
10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
Active Comparator: Individual Prenatal Care
Individual prenatal care
The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perinatal Depression
Time Frame: Baseline visit
Major Depression (Edinburgh Postnatal Depression Scale Score, range: 0-30, higher scores are a worse outcome)
Baseline visit
Perinatal Depression
Time Frame: 28-40 week visit
Major Depression (Edinburgh Postnatal Depression Scale Score, range: 0-30, higher scores are a worse outcome)
28-40 week visit
Perinatal Depression
Time Frame: 4-12 weeks Postpartum
Major Depression (Edinburgh Postnatal Depression Scale Score, range: 0-30, higher scores are a worse outcome)
4-12 weeks Postpartum

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Preterm Birth
Time Frame: Delivery
Delivery at <37 weeks gestation
Delivery
Small for Gestational Age
Time Frame: Delivery
Birthweight <10th percentile on the Alexander growth curve
Delivery
Perceived Stress
Time Frame: Baseline visit
Perceived Stress Scale Total Scores, range: 0-40, higher scores are a worse outcome
Baseline visit
Perceived Stress
Time Frame: 28-40 week
Perceived Stress Scale Total Scores, range: 0-40, higher scores are a worse outcome
28-40 week
Perceived Stress
Time Frame: 4-12 weeks Postpartum
Perceived Stress Scale Total Scores, range: 0-40, higher scores are a worse outcome
4-12 weeks Postpartum
Anxiety
Time Frame: Baseline visit
PROMIS Short Form Anxiety 8a T-Score, range: 37.1-83.1, higher scores are a worse outcome
Baseline visit
Anxiety
Time Frame: 28-40 week visit
PROMIS Short Form Anxiety 8a T-Score, range: 37.1-83.1, higher scores are a worse outcome
28-40 week visit
Anxiety
Time Frame: 4-12 weeks Postpartum
PROMIS Short Form Anxiety 8a T-Score, range: 37.1-83.1, higher scores are a worse outcome
4-12 weeks Postpartum
Post-Traumatic Stress Disorder (PTSD)
Time Frame: Baseline Visit
PTSD Checklist for DSM-V Total Symptom Severity Score, range 0-80, higher scores are a worse outcome
Baseline Visit
Social Support
Time Frame: Baseline visit
PROMIS Bank 2.0 Social Support (emotional support, instrumental support, informational support, and social isolation domains) T-Scores, range 23.7-76.9, higher scores are better outcomes for emotional support, instrumental support and informational support, higher scores are worse outcomes for social isolation
Baseline visit
Social Support
Time Frame: 28-40 week visit
PROMIS Bank 2.0 Social Support (emotional support, instrumental support, informational support, and social isolation domains) T-Scores, range 23.7-76.9, higher scores are better outcomes for emotional support, instrumental support and informational support, higher scores are worse outcomes for social isolation
28-40 week visit
Social Support
Time Frame: 4-12 weeks Postpartum
PROMIS Bank 2.0 Social Support (emotional support, instrumental support, informational support, and social isolation domains) T-Scores, range 23.7-76.9, higher scores are better outcomes for emotional support, instrumental support and informational support, higher scores are worse outcomes for social isolation
4-12 weeks Postpartum
Race-Related Stress
Time Frame: Baseline visit
Index of Race Related Stress-Brief Version Total Score, range 0-22, higher scores are worse outcomes
Baseline visit
Maternal Attachment (Antenatal)
Time Frame: Baseline visit
Maternal Antenatal Attachment Scale Total Score, range 19-95, higher scores are better outcomes
Baseline visit
Maternal Attachment (Antenatal)
Time Frame: 28-40 week visit
Maternal Antenatal Attachment Scale Total Score, range 19-95, higher scores are better outcomes
28-40 week visit
Maternal Attachment (Postnatal)
Time Frame: 4-12 Weeks Postpartum
Maternal Postnatal Attachment Scale Total Score, range 19-95, higher scores are better outcomes
4-12 Weeks Postpartum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 21, 2021

Primary Completion (Estimated)

June 30, 2025

Study Completion (Estimated)

June 30, 2025

Study Registration Dates

First Submitted

March 18, 2021

First Submitted That Met QC Criteria

April 6, 2021

First Posted (Actual)

April 9, 2021

Study Record Updates

Last Update Posted (Actual)

December 5, 2023

Last Update Submitted That Met QC Criteria

November 28, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 202103142

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy Related

Clinical Trials on EleVATE Group Care

3
Subscribe